Pleven

• A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD Ended recruitment
  2025-523020-50-00 4 2026-03-04 Chronic Obstructive Pulmonary Disease
• A Study Evaluating BFB759 in Atopic Dermatitis Ended recruitment
  2025-521624-30-00 4 2026-01-08 Atopic dermatitis
• A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis Ended recruitment
  2025-522113-35-00 4 2026-01-07 Atopic dermatitis
• SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended recruitment
  2025-521791-63-00 4 2025-12-18 Moderately to Severely Active Rheumatologic Disease
• Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended recruitment
  2024-516295-14-00 4 2025-09-17 Treatment of Sjögren’s disease
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici … Ended recruitment
  2025-521127-73-00 5 2025-09-12 Relapsing forms of Multiple Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally i … Ended recruitment
  2024-519919-34-00 5 2025-08-18 Plaque psoriasis
• Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants … Ended recruitment
  2024-512319-40-00 5 2025-07-01 Subjects with relapsing multiple sclerosis (relapsing remitting MS or
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT … Ended recruitment
  2024-515523-11-00 5 2025-06-09 Chronic Weight Management
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended recruitment
  2024-515672-12-00 5 2025-05-27 Moderate to Severe Genital Psoriasis
• A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph … Ended recruitment
  2024-515162-13-00 5 2025-04-29 Eosinophilic Asthma
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t … Ended recruitment
  2024-512496-12-00 5 2025-04-01 Moderate to Severe Plaque Psoriasis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) ( … Ended recruitment
  2024-514283-40-00 4 2024-12-19 Pulmonary Hypertension
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Ended recruitment
  2024-512113-41-00 5 2024-11-20 Severe Asthma
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended recruitment
  2023-509302-30-00 5 2024-11-04 Hypertriglyceridemia

Showing 121–144 of 287 trials